Industry-academia-government joint research in the Healthcare business

「We are conducting research on extracts of IT Hanabiratake with an external private research institute, and invested ¥3 million in R&D during the consolidated fiscal year.」

「As announced on 14 April 2022, a paper was published in the journal Applied Pharmacology under the title “A double-blind, placebo-controlled, randomized human study evaluating the efficacy and safety of Hanabiratake in alleviating unpleasant symptoms associated with menopause in women.” Based on this paper, we plan to proceed with a notification for a food with function claims. With the efficacy of IT Hanabiratake for menopausal women now academically demonstrated, we will focus primarily on women experiencing menopause and pursue product development with greater emphasis on functionality.」

「In the healthcare business, we are conducting research with an external private research institute on extracts of IT Hanabiratake.」

「We believe scientific evidence is necessary to further raise awareness of Hanabiratake, and are focusing on elucidating the mechanism of action and identifying the constituents responsible for the silent estrogenic activity contained in Hanabiratake.」

「The market for supplements addressing women-specific health concerns is expanding. As a result of our active sales efforts to date, major companies have shown strong interest in Hanabiratake targeting menopausal women. By identifying the constituents of Hanabiratake, elucidating its mechanisms of action and promoting its efficacy, we aim to develop products in collaboration with major companies.」

「For these reasons, we recorded research and development expenses of ¥29 million for the consolidated fiscal year.」

「In the financial solutions business, we are developing Spider, a library-based solution capable of handling all types of financial instrument trading operations in the rapidly changing financial industry. In the healthcare business, we are also conducting joint research with an external private research institute on extracts of IT Hanabiratake. For these reasons, we recorded research and development expenses of ¥338 million for the consolidated fiscal year.」

「In terms of earnings, the segment loss declined as gross profit increased with the expansion of sales of “IT maitake”-related products and research and development expenses for “IT maitake” decreased from the same period of the previous year.」

「In terms of earnings, the segment loss declined as gross profit increased with the expansion of sales of “IT maitake”-related products and research and development expenses for “IT maitake” decreased from the same period of the previous year.」

「In terms of earnings, the segment loss declined substantially as sales of maitake-related products expanded and research and development expenses related to “IT maitake” decreased from the same period of the previous year.」

「In the Financial Solutions business, we are developing “Spider,” a library-based solution capable of supporting all types of financial instrument trading operations in a rapidly changing financial industry. In the Healthcare business, we are conducting industry-academia joint research with Tokyo Women's Medical University and our group on extracts from maitake mushrooms produced by the company. Based on these factors, we recorded research and development expenses of ¥85 million for the fiscal year.」

「The segment loss narrowed partly because research and development expenses related to “IT maitake” decreased substantially from the same period of the previous year and because inventory write-downs had been recorded in the same period of the previous year.」

「The research results for “IT maitake” produced by the company were recognized, and the product received Japan's first Superfood certification as an ingredient from the Japan Superfoods Association. It was also featured in Nikkei Trendy magazine as a notable ingredient for 2018, among other achievements that raised awareness.」

「To further clarify the benefits and efficacy of maitake, the company announced the results of the “IT Maitake Project,” an industry-academia-government joint research project launched in 2014. The results were recognized, and the company's “IT maitake” was adopted for a new business of RIZAP Co., Ltd., a major beauty and health company, among other achievements that raised awareness.」

「The increase from the same period of the previous year in upfront investment, including research and development expenses for joint research and the development of maitake formulations in the People's Republic of Bangladesh」

「The increase from the same period of the previous year in research and development expenses related to industry-academia-government joint research with Tokyo Women's Medical University and the National Institute of Advanced Industrial Science and Technology」

「In terms of expenses, research and development expenses related to industry-academia-government joint research with Tokyo Women's Medical University and the National Institute of Advanced Industrial Science and Technology increased from the same period of the previous year, resulting in a slight deterioration in the segment loss.」

「Research and development expenses related to industry-academia-government joint research with Tokyo Women's Medical University and the National Institute of Advanced Industrial Science and Technology decreased from the previous fiscal year, although the decrease was in line with the original plan.」

「Research and development expenses related to industry-academia-government joint research with Tokyo Women's Medical University and the National Institute of Advanced Industrial Science and Technology decreased from the same period of the previous year, although the decrease was in line with the original plan.」